Concepts (68)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Cardiovascular | 3 | 2024 | 34 | 1.800 |
Why?
|
| Anticoagulants | 5 | 2024 | 57 | 1.260 |
Why?
|
| Warfarin | 3 | 2024 | 19 | 1.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2024 | 9 | 0.940 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 8 | 0.740 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 12 | 0.730 |
Why?
|
| Pregnancy | 7 | 2024 | 1862 | 0.430 |
Why?
|
| Pregnancy Outcome | 2 | 2024 | 117 | 0.400 |
Why?
|
| Thrombosis | 2 | 2023 | 47 | 0.390 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 27 | 0.380 |
Why?
|
| Retrospective Studies | 2 | 2024 | 799 | 0.330 |
Why?
|
| Female | 10 | 2024 | 9103 | 0.300 |
Why?
|
| Enoxaparin | 2 | 2024 | 14 | 0.290 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2002 | 3 | 0.240 |
Why?
|
| Bioprosthesis | 1 | 2024 | 8 | 0.240 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 7 | 0.240 |
Why?
|
| Abortion, Spontaneous | 1 | 2024 | 15 | 0.230 |
Why?
|
| Humans | 10 | 2024 | 14537 | 0.230 |
Why?
|
| South Africa | 5 | 2024 | 7596 | 0.230 |
Why?
|
| Menorrhagia | 1 | 2024 | 1 | 0.230 |
Why?
|
| Embolism | 1 | 2023 | 4 | 0.210 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2002 | 115 | 0.210 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2022 | 5 | 0.200 |
Why?
|
| Quality of Life | 1 | 2024 | 177 | 0.200 |
Why?
|
| Nervous System Malformations | 1 | 2021 | 1 | 0.190 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 80 | 0.170 |
Why?
|
| Prothrombin | 1 | 2019 | 8 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 7 | 0.170 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2019 | 9 | 0.170 |
Why?
|
| Adult | 4 | 2024 | 5913 | 0.160 |
Why?
|
| Mutation | 1 | 2019 | 306 | 0.150 |
Why?
|
| Young Adult | 1 | 2024 | 2498 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2021 | 1479 | 0.130 |
Why?
|
| Infant | 1 | 2021 | 2244 | 0.120 |
Why?
|
| Risk Factors | 2 | 2024 | 1475 | 0.070 |
Why?
|
| Middle Aged | 3 | 2024 | 3601 | 0.060 |
Why?
|
| Rivaroxaban | 1 | 2024 | 6 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2024 | 127 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2023 | 11 | 0.050 |
Why?
|
| HIV Infections | 1 | 2021 | 5097 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2023 | 89 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2023 | 72 | 0.050 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2022 | 4 | 0.050 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2022 | 4 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2022 | 5 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 2002 | 3 | 0.050 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2022 | 9 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 24 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2002 | 34 | 0.050 |
Why?
|
| Incidence | 1 | 2024 | 685 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2001 | 3 | 0.050 |
Why?
|
| Fetus | 1 | 2021 | 8 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 25 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 26 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 435 | 0.050 |
Why?
|
| Biopsy | 1 | 2001 | 38 | 0.050 |
Why?
|
| Parity | 1 | 2001 | 19 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2001 | 50 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2001 | 149 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2002 | 74 | 0.050 |
Why?
|
| Prognosis | 1 | 2001 | 199 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2024 | 1160 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 231 | 0.040 |
Why?
|
| Aged | 2 | 2002 | 1740 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 480 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2001 | 889 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 10 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 260 | 0.010 |
Why?
|